Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

By A. Cranney, G. Guyatt, L. Griffith, G. Wells, Peter Tugwell, C. Rosen. Endocrine reviews, 2002

599 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. (2005, background): “Both alendronate and risedronate reduce the incidence of vertebral fractures by 40–50% in women known to have osteoporosis (9–14), with similar reductions in nonvertebral fractures (15).”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, background): “Calcitonin likely reduces the risk of vertebral fracture; however, the magnitude of the impact on these fractures remains questionable [175].”
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. (2003, background): “The Osteoporosis Research Advisory Group (ORAG) has provided a comprehensive review of the randomized trials of osteoporosis therapies.(37) Vitamin D (hydroxylated), calcitonin, raloxifene, the bisphosphonates, etidronate, risedronate, and alendronate all reduced vertebral fractures with the stronge”